Perfil
Andrea Grant served as the Chief Executive Officer, Executive Director & MD at Algorae Pharmaceuticals Ltd.
from 2012 to 2014.
Prior to that, she was the Chief Executive Officer at Diatranz Otsuka Ltd.
and the Managing Director at Galapagos Genomics NV.
Dr. Grant received her undergraduate and doctorate degrees from the University of Cambridge.
Antiguos cargos conocidos de Andrea Grant.
| Empresas | Cargo | Fin |
|---|---|---|
| ALGORAE PHARMACEUTICALS LIMITED | Director Ejecutivo | 01/04/2014 |
Galapagos Genomics NV
 Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Corporate Officer/Principal | 02/05/2008 |
Diatranz Otsuka Ltd.
 Diatranz Otsuka Ltd. Pharmaceuticals: MajorHealth Technology Diatranz Otsuka Ltd. manufactures pharmaceutical products. Its product, DIABECELL, is used to treat type1 diabetes. The company was founded on November 11, 2011 and is headquartered in Auckland, New Zealand. | Director Ejecutivo | - |
Formación de Andrea Grant.
| University of Cambridge | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ALGORAE PHARMACEUTICALS LIMITED | Health Technology |
| Empresas privadas | 2 |
|---|---|
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Diatranz Otsuka Ltd.
Diatranz Otsuka Ltd. Pharmaceuticals: MajorHealth Technology Diatranz Otsuka Ltd. manufactures pharmaceutical products. Its product, DIABECELL, is used to treat type1 diabetes. The company was founded on November 11, 2011 and is headquartered in Auckland, New Zealand. | Health Technology |
- Bolsa de valores
- Insiders
- Andrea Grant
